About Immune Targeting Systems
Immune Targeting Systems is a company based in London (United Kingdom) founded in 2003 was acquired by Altimmune in February 2015. Immune Targeting Systems has raised $20.3 million across 2 funding rounds from investors including Altimmune, Truffle Capital and London Technology Fund. The company has 46 employees as of December 31, 2021. Immune Targeting Systems operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter London, United Kingdom
- Employees 46 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Altimmune Uk Limited
- Date of Incorporation 05 Oct, 1992
- Jurisdiction LEEDS, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immune Targeting Systems
Immune Targeting Systems has successfully raised a total of $20.3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $13.2 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immune Targeting Systems
Immune Targeting Systems has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Altimmune, Truffle Capital and London Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Immune Targeting Systems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immune Targeting Systems
Investment portfolio details for Immune Targeting Systems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immune Targeting Systems
Detailed financials for Immune Targeting Systems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immune Targeting Systems Comparisons
Peer comparison for Immune Targeting Systems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immune Targeting Systems
Immune Targeting Systems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Developer of computationally designed VLP vaccines for treating multiple infections
|
Detailed competitors of Immune Targeting Systems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immune Targeting Systems
Complete news archive for Immune Targeting Systems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immune Targeting Systems
Immune Targeting Systems was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Immune Targeting Systems is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Immune Targeting Systems is a funded company, having raised a total of $20.3M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Immune Targeting Systems is 46.
Immune Targeting Systems was founded in 2003 in London, United Kingdom, within the biotechnology sector. Prophylactic and therapeutic vaccines targeting mutating viruses are developed using a fluorocarbon-conjugated synthetic peptide platform. Broad HLA and antigen coverage, along with product stability, are achieved in these T-cell vaccines. Protection against infectious diseases is provided, including Flunisyn as a depot vaccine for influenza. The company was acquired by Vaxin in February 2015.
Immune Targeting Systems's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Immune Targeting Systems has 5 investors. Key investors include Altimmune, Truffle Capital, London Technology Fund, Novartis Venture Fund, and Healthcap.